For the quarter ending 2025-09-30, SRTAW had $3,369K increase in cash & cash equivalents over the period. -$48,354K in free cash flow.
| Cash Flow | 2025-09-30 |
|---|---|
| Net income (loss) | 50,180 |
| Gain on sale of business | 60,435 |
| Depreciation and amortization | 5,177 |
| Stock-based compensation | 11,246 |
| Change in fair value of warrant liabilities | -2,862 |
| Excess of lease liability over operating right-of-use assets | 0 |
| Transaction costs paid related to sale of business | 5,964 |
| Acquisition consideration allocated to seller transaction expenses | 44,339 |
| Impairment of intangible assets | 0 |
| Realized loss from sales of short-term investments | -5,195 |
| Realized foreign exchange gain | 798 |
| Accretion of interest income on held-to-maturity securities | 1,732 |
| Deferred tax expense (benefit) | 558 |
| Other | 388 |
| Prepaid expenses and other current assets | -776 |
| Accounts receivable | 8,551 |
| Other non-current assets | -666 |
| Operating right-of-use assets/lease liabilities | 90 |
| Accounts payable and accrued expenses | 8,395 |
| Other current liabilities | 1,583 |
| Net cash used in operating activities | -40,607 |
| Acquisitions, net of cash acquired | 65,174 |
| Cash transfer from sale of business | 1,241 |
| Capitalized software development costs | 1,258 |
| Payments for (proceeds from) productive assets | 7,747 |
| Purchase of held-to-maturity investments | 146,258 |
| Proceeds from maturities of held-to-maturity investments | 203,000 |
| Proceeds from sale of short-term investments | 70,163 |
| Net cash provided by / (used in) investing activities | 51,485 |
| Proceeds from the exercise of common stock options | 139 |
| Taxes paid related to net share settlement of equity awards | 7,309 |
| Repurchase and retirement of common stock | 0 |
| Net cash used in financing activities | -7,170 |
| Effect of foreign exchange rate changes on cash balances | -339 |
| Net increase (decrease) in cash and cash equivalents and restricted cash | 3,369 |
| Cash and cash equivalents at beginning of period | 19,647 |
| Cash and cash equivalents at end of period | 23,016 |
Strata Critical Medical, Inc. (SRTAW)
Strata Critical Medical, Inc. (SRTAW)